2026-10-30 06:00:01 UTC#543109newconfirmedanalysis
NVS stock news
NVS stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-29 16:57:00 UTC#539228newconfirmedanalysis
Bernstein cuts Novartis price target to 127.08 francs, citing need for pipeline clarity to meet 2030s growth goals
2026-10-29 04:20:00 UTC#534177newconfirmednews
Novartis AG average analyst price target raised to $158.20, implying 1% upside
2026-10-28 11:00:00 UTC#527982newconfirmedpress release
Monte Rosa Therapeutics announces Novartis initiated second Phase 2 study for MRT-6160 in psoriatic arthritis
yahooimportance 0.40trust 0.90Monte Rosa Therapeutics, Inc. +0.50Novartis AG +0.50MRT-6160 +0.50+1 entities
2026-10-27 15:20:39 UTC#522351updateconfirmednews
Novartis Q3 growth driven by priority brands; $1.9B impairment noted alongside 2026 guidance upgrade
2026-10-27 15:15:31 UTC#522307duplicateconfirmednews
Novartis records $1.9bn impairment charge on rare-disease drug, raises FY profit outlook
2026-10-27 14:21:00 UTC#521999duplicateconfirmednews
Novartis raises 2026 core operating profit guidance to low-single-digit growth, citing AI-driven cost savings
2026-10-27 14:06:00 UTC#521937duplicateconfirmednews
Novartis discontinues late-stage remibrutinib trial for myasthenia gravis due to lack of efficacy
2026-10-27 13:51:00 UTC#521781updateconfirmednews
Novartis discontinues late-stage remibrutinib trial in generalized myasthenia gravis due to lack of efficacy
2026-10-27 12:48:13 UTC#521378duplicateconfirmednews
Novartis raises full-year earnings guidance despite Q3 Kisqali sales miss
2026-10-27 12:43:00 UTC#521331newconfirmednews
WSJ Health Care Market Talk: Insights on Novartis and Genmab
2026-10-27 11:57:03 UTC#520950newconfirmednews
Novartis AG Q3 2026 earnings call begins
2026-10-27 10:57:47 UTC#520842duplicateconfirmednews
European shares decline as HSBC earnings miss and French political unrest weigh on sentiment
zerodha pulseimportance 0.30trust 0.60HSBC Holdings plc -0.50Novartis AG +0.40France -0.30+1 entities
2026-10-27 10:47:11 UTC#520348duplicateconfirmednews
Novartis raises FY profit outlook as new drug sales offset generic competition
2026-10-27 09:07:00 UTC#519691duplicateconfirmednews
Novartis raises full-year earnings guidance despite Q3 clinical trial setbacks
2026-10-27 08:52:00 UTC#519627duplicateconfirmednews
Novartis raises FY earnings guidance despite Q3 clinical trial setbacks for pelacarsen and del-desiran
2026-10-27 08:30:48 UTC#519538duplicateconfirmednews
Novartis AG Q3 adjusted EPS $2.46 beats $2.29 estimate, revenue $14.52B beats $14.47B forecast
2026-10-27 06:58:16 UTC#519073newconfirmednews
Novartis CEO confirms current M&A strategy remains unchanged
2026-10-27 06:52:15 UTC#519057duplicateconfirmednews
Novartis raises FY core operating income guidance, records $1.9B impairment charge for del-desiran trial failure
2026-10-27 06:36:00 UTC#519012duplicateconfirmednews